BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 27135782)

  • 1. CXCR4 Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group.
    Matsuo H; Nakamura N; Tomizawa D; Saito AM; Kiyokawa N; Horibe K; Nishinaka-Arai Y; Tokumasu M; Itoh H; Kamikubo Y; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Tanaka S; Adachi S
    Pediatr Blood Cancer; 2016 Aug; 63(8):1394-9. PubMed ID: 27135782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.
    Qin YZ; Zhu HH; Jiang Q; Jiang H; Zhang LP; Xu LP; Wang Y; Liu YR; Lai YY; Shi HX; Jiang B; Huang XJ
    Leuk Res; 2014 Dec; 38(12):1435-40. PubMed ID: 25449688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of CXCR4 in acute myeloid leukemia.
    Ahn JY; Seo K; Weinberg OK; Arber DA
    Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):79-84. PubMed ID: 22914607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.
    Yui S; Kurosawa S; Yamaguchi H; Kanamori H; Ueki T; Uoshima N; Mizuno I; Shono K; Usuki K; Chiba S; Nakamura Y; Yanada M; Kanda J; Tajika K; Gomi S; Fukunaga K; Wakita S; Ryotokuji T; Fukuda T; Inokuchi K
    Ann Hematol; 2017 Oct; 96(10):1641-1652. PubMed ID: 28762080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
    Pollard JA; Alonzo TA; Gerbing RB; Ho PA; Zeng R; Ravindranath Y; Dahl G; Lacayo NJ; Becton D; Chang M; Weinstein HJ; Hirsch B; Raimondi SC; Heerema NA; Woods WG; Lange BJ; Hurwitz C; Arceci RJ; Radich JP; Bernstein ID; Heinrich MC; Meshinchi S
    Blood; 2010 Mar; 115(12):2372-9. PubMed ID: 20056794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between CXC chemokine receptor 4 expression and prognostic significance in acute myeloid leukemia.
    Cao T; Ye Y; Liao H; Shuai X; Jin Y; Su J; Zheng Q
    Medicine (Baltimore); 2019 Jun; 98(23):e15948. PubMed ID: 31169718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia.
    Gao X; Lin J; Gao L; Deng A; Lu X; Li Y; Wang L; Yu L
    PLoS One; 2015; 10(4):e0124241. PubMed ID: 25860287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype.
    Konoplev S; Rassidakis GZ; Estey E; Kantarjian H; Liakou CI; Huang X; Xiao L; Andreeff M; Konopleva M; Medeiros LJ
    Cancer; 2007 Mar; 109(6):1152-6. PubMed ID: 17315232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VLA-4 and CXCR4 expression levels show contrasting prognostic impact (favorable and unfavorable, respectively) in acute myeloid leukemia.
    Bae MH; Oh SH; Park CJ; Lee BR; Kim YJ; Cho YU; Jang S; Lee JH; Kim N; Park SH; Lim JH; Seo EJ; Lee KH
    Ann Hematol; 2015 Oct; 94(10):1631-8. PubMed ID: 26155911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High receptor tyrosine kinase (FLT3, KIT) transcript versus anti-apoptotic (BCL2) transcript ratio independently predicts inferior outcome in pediatric acute myeloid leukemia.
    Sharawat SK; Bakhshi R; Vishnubhatla S; Bakhshi S
    Blood Cells Mol Dis; 2015 Jan; 54(1):56-64. PubMed ID: 25216797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group.
    Shimada A; Taki T; Tabuchi K; Tawa A; Horibe K; Tsuchida M; Hanada R; Tsukimoto I; Hayashi Y
    Blood; 2006 Mar; 107(5):1806-9. PubMed ID: 16291592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCL3 Expression Is a Potential Prognostic and Predictive Biomarker in Acute Myeloid Leukemia of FAB Subtype M2.
    Niu Y; Yang X; Chen Y; Zhang L; Jin X; Tang Y; Li L; Yu L; Guo Y; Wang H
    Pathol Oncol Res; 2019 Apr; 25(2):541-548. PubMed ID: 30357752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased coexpression of c-KIT and FLT3 receptors on myeloblasts: independent predictor of poor outcome in pediatric acute myeloid leukemia.
    Sharawat SK; Gupta R; Raina V; Kumar L; Sharma A; Iqbal S; Bakhshi R; Vishnubhatla S; Bakhshi S
    Cytometry B Clin Cytom; 2013; 84(6):390-7. PubMed ID: 23740774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
    Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
    Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia.
    Chen X; Dou H; Wang X; Huang Y; Lu L; Bin J; Su Y; Zou L; Yu J; Bao L
    Leuk Lymphoma; 2018 Apr; 59(4):829-836. PubMed ID: 28792268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NPM1, FLT3, and c-KIT mutations in pediatric acute myeloid leukemia in Russian population.
    Yatsenko Y; Kalennik O; Maschan M; Kalinina I; Maschan A; Nasedkina T
    J Pediatr Hematol Oncol; 2013 Apr; 35(3):e100-8. PubMed ID: 23511494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of Adolescents and Young Adults Compared With Pediatric Patients With Acute Myeloid and Promyelocytic Leukemia.
    Nasir SS; Giri S; Nunnery S; Martin MG
    Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):126-132.e1. PubMed ID: 27836483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Core binding factor acute myeloid leukaemia and c-KIT mutations.
    Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
    Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.
    Paschka P; Marcucci G; Ruppert AS; Mrózek K; Chen H; Kittles RA; Vukosavljevic T; Perrotti D; Vardiman JW; Carroll AJ; Kolitz JE; Larson RA; Bloomfield CD;
    J Clin Oncol; 2006 Aug; 24(24):3904-11. PubMed ID: 16921041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia.
    Konoplev S; Lin P; Yin CC; Lin E; Nogueras González GM; Kantarjian HM; Andreeff M; Medeiros LJ; Konopleva M
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):686-92. PubMed ID: 24035716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.